Deregulated Bcr-Abl TK activity is the target for the new, very effective agents introduced to first line CML therapy – BCR-ABL TK inhibitors (TKIs): imatinib, dasatinib, and nilotinib. Here, TKT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.